NYSE:PENMedical Equipment
Penumbra (PEN) Reports THUNDERBOLT Study Success As First Stroke Treatment Use Begins
Penumbra (NYSE:PEN) reported key clinical results from its THUNDER study, indicating the THUNDERBOLT stroke treatment system met safety and effectiveness goals.
The THUNDERBOLT system has now seen its first clinical use following recent FDA clearance, with initial adoption at a leading neuroscience institute.
These updates add new clinical and real-world data points beyond prior announcements on the FORWARD study and regulatory clearance.
For investors tracking Penumbra, the THUNDERBOLT...